

COVID-19 Immunization Screening and Consent Form*

Rec	pient Name (please print)	Preferred Name						
DOE	Current Gender ID Key: W – Woman	 n/Girl TW – Transgender Woman/Girl M – Man/Boy						
	Indicate ID Deleve							
		• •	not to Respond	ender me				
		er not Listed (write-in)						
		ronouns: write-in by client's nam	ie					
Sex	Assigned at Birth Key:	Marital Status Key:						
	cate Sex Below:		- Single D – Divord	ed M	– Married			
	M – Male F – Female	w w	– Widowed V – Civil U	nion U –	Unknown			
	I – Intersex NR – Chose not to Respond	SE SE	PARATED – Legally Sep	parated				
		PARTNER – Life Partner						
Add	ress City	State Zip	Email Address					
Pare	ent/Guardian/ Surrogate (if applicable, please print)	Phone	Preferred Language					
Tare	int/ Guardian/ Surrogate (ii applicable, picase print)	Thone	Treferred Ediffdage					
Ethr	nicity Ethnicity Key:	Race Race Ke	\ <u>\</u>					
	cate Ethnicity Below: DECL – Declined	Indicate Race Below: AIA – Na		an ΔSI	N – Asian			
IIIui	HIS – Hispanic Origin		frican American or Blac		Asian			
	NHL – Non-Hispanic Origin	DECL - D		J.K				
Ь	UNK – Unknown		ative Hawaiian or Pacif	fic Islande	ar			
	OTAK OTIKITOWIT	WHT – V			er or Multiracia			
Prin	nary Insurance Name	Primary Insurance ID#	Subscriber Name/DO		scriber Relation			
	iary insurance itame	Trimary modulee 1511	Subscriber Name, Do		atient			
					aciene			
Prin	nary Insurance Address	Primary Insurance Group #	Primary Insurance Phone #					
		,	,					
Seco	ondary Insurance Name	Secondary Insurance ID#	Subscriber Name/DO	er Name/DOB Subscribe				
5000	stradity insurance realine	Secondary insurance isin	Subscriber Name, Do		atient			
					aciene			
Seco	ondary Insurance Address	Secondary Insurance Group #	Secondary Insurance Phone #					
	,	,	,					
Clin	ic/Office Site Where Vaccine is Administered	Primary Care Physician Addres	s/Phone Number					
Ciiii	of office site where vaccine is Autilinistered	Primary Care Physician Address/Phone Number						
	Scree	ening Questionnaire		1	<u> </u>			
1.	Are you feeling sick today?		□ Yes	□ No				
2.	In the last 10 days, have you had a COVID-19 tes	t because you had symptoms a	nd are still Yes	□ No	□ Unknown			
	awaiting your test results or been told by a heal		artment to					
	isolate orquarantine at home due to COVID-19 infe	ection or exposure?						
3.	Have you been treated with antibody therapy or con	valescent plasma for COVID-19 in	the past 90 🗆 Yes	□ No	□ Unknown			
	days (3 months)? If yes, when did you receive the le	The state of the s	_					
4.	Have you ever had an immediate allergic reaction (e	g hives facial swelling difficulty	breathing, Yes	□ No	□ Unknown			
→.	anaphylaxis) to any vaccine, injection, or shot or to a	· · · · · · · · · · · · · · · · · · ·			- CHRIOWII			
	severe allergic reaction (anaphylaxis) to anything?	,						
\vdash		-+1		- N-	_ 11-1			
5.	Are you pregnant or considering becoming pregnan	ווני	□ Yes	□ No	□ Unknown			

6.	Do you have cancer, leukemia, HIV/AIDS or any other condition that weakens the immune system?		Yes		No	□ Unknown
7.	Do you take any medications that affect your immune system, such as cortisone, prednisone or other steroids, anticancer drugs, or have you had any radiation treatments?	□ Yes □ No □ Unknown				
8.	Do you have a bleeding disorder, a history of blood clots or are you taking a blood thinner?		Yes		No	□ Unknown
9.	Do you have a history of myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining around the heart)?		Yes		No	□ Unknown
10.	Are you 16 years old or older, and have you received 2 doses of the Pfizer vaccine, the second dose being at least 6 months ago?		Yes		No	Date of 2 nd dose: (if applicable
11.	Have you received 2 doses of the Moderna vaccine, the second dose being at least 6 months ago?		Yes		No	Date of 2 nd dose:
12.	Have you received a previous dose of the Janssen vaccine, at least 2 months ago?		Yes		No	Date of 1 st dose:
13.	If you had a previous dose of Janssen (Johnson & Johnson), did you develop thrombosis with thrombocytopenia syndrome (TTS)?		Yes		No	□ Unknown
14.1	Have you received a previous dose of a non-FDA authorized or approved COVID-19 vaccine authorized by the WHO¹ but not by the FDA (AstraZeneca – VAXZEVRIA, Sinovac – CORONAVAC, Serum Institute of India – COVISHIELD, Sinopharm/BIBP, COVAXIN)?		Yes		No	□Unknown

^{*}Questions #10 - 14 pertain to booster dose eligibility.

Emergency Use Authorization

The FDA has made the COVID-19 vaccine available under an emergency use authorization (EUA). The EUA is used when circumstances exist to justify the emergency use of drugs and biological products during an emergency, such as the COVID-19 pandemic. This vaccine has not undergone the same type of review as an FDA-approved or cleared product. However, the FDA's decision to make the vaccine available is based on the totality of scientific evidence available, showing that known and potential benefits of the vaccine outweigh the known and potential risks. Please note: FDA approved the Pfizer-BioNTech COVID-19 vaccine as a two-dose series in individuals 16 years of age and older. The vaccine continues to be available under an EUA for certain populations, including for those individuals 5 through 15 years of age and for the administration of a third dose in the populations set forth in the consent section below.

Emergency Use Instruction

Emergency Use Instructions (EUIs) are issued by the CDC to provide information about emergency use of FDA-approved medical products that may not be included in or differ in some way from the information provided in the FDA-approved labeling (package insert). The COVID-19 vaccine by Pfizer-BioNTech is an FDA-approved COVID-19 vaccine (brand name Comirnaty, mRNA) to prevent COVID-19 in persons 16 years of age and older. CDC is issuing EUI to provide information about use of this vaccine as an additional primary dose in certain immunocompromised persons (12 years of age and older) and a booster dose in certain adults (18 years of age and older) who received certain non-FDA authorized or approved COVID-19 vaccine (e.g., certain vaccines available outside of the United States or from clinical trial participation).

Consent

I have read, or had explained to me, the information sheet about the COVID-19 vaccination. I understand that if my vaccine requires two doses, I will need to be administered (given) two doses to be considered fully vaccinated. Further, I understand that a booster dose of COVID-19 vaccine is recommended at least 2 months following the first dose of Janssen vaccine (if I am age 18 or older), or at least 6 months following the second dose of Pfizer-BioNTech (if I am age 16 or older) or Moderna COVID-19 vaccine (if I am age 18 or older), to increase my protection.

I have had a chance to ask questions which were answered to my satisfaction (and ensured the person named above for whom I am authorized to provide surrogate consent was also given a chance to ask questions). I understand the benefits and risks of the vaccination as described.

I request that the COVID-19 vaccination be given to me (or the person named above for whom I am authorized to make this request and provide surrogate consent). I understand there will be no cost to me for this vaccine. I understand that any monies or benefits for administering the vaccine will be assigned and transferred to the vaccinating provider, including benefits/monies from my health plan, Medicare or other third parties who are financially responsible for my medical care. I authorize release of all information needed (including but not limited to medical records, copies of claims and itemized bills) to verify payment and as needed for other public health purposes, including reporting to applicable vaccine registries.

¹As set forth in the <u>CDC's Emergency Use Instructions</u>, a non-FDA authorized or approved COVID-19 vaccine such as those vaccines "listed for emergency use by the World Health Organization, or is included in CDC's Technical Instructions for Implementing Presidential Proclamation Advancing Safe Resumption of Global Travel During the COVID-19 Pandemic and CDC's Order, or that is a non-placebo part of a clinical trial within or outside the United States that is a WHO-EUL COVID-19 vaccine or a vaccine that is not listed for emergency use by WHO but for which a U.S. data and safety monitoring board or equivalent has independently confirmed efficacy in the United States (hereinafter "non-FDA authorized or approved COVID-19 vaccines").

Recipient/Surrogate/Grecipient	uardian (Signature)	Date / Time	Print Name		ationship to Patient other than recipient)					
Telephonic Interpreter'	s ID #	Date / Time								
Signature: Interpreter		Date/ Time	Print: Interpreter's Name and Relationship to Patient							
Area Below to be Completed by Vaccinator										
Which vaccine is the	e patient receiving to	day?								
Vaccine Name		Administration	า	EUA Fact Sheet Date	Manufacturer & Lot #					
Pfizer/BioNTech	□ First Dose	□ Second Dose	□ Booster Dose							
Moderna	□ First Dose	□ Second Dose	□ Booster Dose							
Janssen	☐ Single Dose	□ Booster Dose								
Administration Site	Left Deltoid	Right Del	toid 🗆 Left Thi	gh 🗆 Right Thigh						
Dosage	□ 0.5 ml	□ 0.3 ml	□ 0.25 ml							
☐ I have provide and consent to vacc	cination was obtain		n or surrogate, as a	pplicable) with informa	tion about the vaccine					
Use of this form is o	ptional.			Upda	ted December 10, 2021					